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Trachoma, caused by the obligate intracellular 
bacterium Chlamydia trachomatis, is the world’s 
leading cause of infectious blindness. It afflicts 
millions of people in sub-Saharan Africa and 
Asia  (Schachter,  1978).  Trachoma  was  first   
described  in  early  Egyptian  writings  (Taylor, 
2008) and remains one of the world’s most ne-
glected  infectious  diseases  to  this  day  (Vogel, 
2006). Control of trachoma is focused on the im-
plementation of the World Health Organization 
SAFE strategy that is composed of surgery for   
trichiasis, antibiotics for infection, facial cleanli-
ness, and environmental improvements (World 
Health Organization, 1998). Despite its benefits, 
the SAFE strategy is difficult to implement and 
sustain effectively, particularly in the most im-
poverished trachoma endemic communities 
(Lakew et al., 2009; West et al., 2011). Thus, 
these socioeconomic environments require sus-
tainable alternative measures to have a lasting 
impact on trachoma control. Vaccination would 
be an effective way to accomplish this goal.
Trachoma  vaccine  development  is  viewed 
with considerable skepticism, primarily because 
the damaging scarring and blinding complica-
tions of the disease are associated with repeated 
or persistent infections that trigger dominance in 
pathological  rather  than  protective  immunity 
(Schachter, 1985). In contrast, epidemiological 
studies have shown the duration of untreated 
infection becomes shorter with increasing age. 
This  argues  that  naturally  acquired  protective 
immunity  eventually  develops  (Bailey  et  al., 
1999), supporting the idea that an effective tra-
choma vaccine is achievable. The lack of an ex-
perimental  trachoma  small  animal  model,  the 
mucosal  tropism  and  biological  complexity  of 
chlamydial host interactions, and the inability 
to  genetically  manipulate  the  organism  have 
also  been  unfavorable  to  trachoma  vaccine 
development. Moreover, chlamydiae are anti-
genically complex organisms producing numer-
ous structural and secreted antigenic targets that 
elicit distinct immune effector mechanisms. 
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Blinding trachoma is an ancient neglected tropical disease caused by Chlamydia trachomatis 
for which a vaccine is needed. We describe a live-attenuated vaccine that is safe and effica-
cious in preventing trachoma in nonhuman primates, a model with excellent predictive value 
for humans. Cynomolgus macaques infected ocularly with a trachoma strain deficient for the 
7.5-kb conserved plasmid presented with short-lived infections that resolved spontaneously 
without ocular pathology. Multiple infections with the attenuated plasmid-deficient strain 
produced no inflammatory ocular pathology but induced an anti-chlamydial immune re-
sponse. Macaques vaccinated with the attenuated strain were either solidly or partially 
protected after challenge with virulent plasmid-bearing organisms. Partially protected 
macaques shed markedly less infectious organisms than controls. Immune correlates of 
protective immunity were not identified, but we did detect a correlation between MHC class II 
alleles and solid versus partial protection. Epidemiological models of trachoma control 
indicate that a vaccine with this degree of efficacy would significantly reduce the preva-
lence of infection and rates of reinfection, known risk factors which drive blinding disease.
This article is distributed under the terms of an Attribution–Noncommercial– 
Share Alike–No Mirror Sites license for the first six months after the publication 
date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported   
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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that produces protective but not pathological immunity 
(Brunham et al., 2000; Su et al., 2000; Morrison and 
Caldwell, 2002). C. trachomatis organisms possess a con-
served 7.5-kb plasmid of unknown function (Palmer 
and Falkow, 1986). Naturally occurring (Carlson et al., 
2008) or antibiotic-cured (O’Connell et al., 2007) 
nontrachoma plasmid-deficient strains are attenuated 
in mouse models of genital tract infection, implicating 
the plasmid as a key chlamydial virulence factor. We 
hypothesized that a plasmid-deficient trachoma strain 
might be similarly attenuated and serve as a novel 
candidate for a live-attenuated trachoma vaccine. In our study, 
we test this hypothesis and demonstrate that a plasmid-deficient 
trachoma strain is highly attenuated for nonhuman primates 
but induces an immunity that protects against trachoma.
An efficacious vaccine will likely need to satisfy and target these 
unique infection characteristics without stimulating pathologi-
cal immunity. Theoretically, this might be best achieved by a 
live-attenuated vaccine delivered onto the conjunctival surface 
Figure 1.  In vitro characterization of the C. trachomatis 
plasmid-deficient trachoma strain A2497P. (A) The presence 
of eight plasmid open reading frames (pCTA001-008) in A2497 and 
A2497P was measured by PCR. The RNA polymerase  subunit 
(rpoB) was used as a chromosomal-positive control. (B and C) 
A2497 and A2497P were cultured in McCoy cells. (B) In vitro 
growth. n = 3. Error bars indicate standard deviation and results are 
shown for one of two independent experiments. (C) Plaque size. 
n = 2 Results are shown for one of three independent experiments.
Figure 2.  The C. trachomatis plasmid-cured trachoma strain A2497P is highly attenuated for the monkey eye. (A) Six monkeys were infected 
with A2497 (individual data points are plotted). These monkeys are six historic controls from two recent nonhuman primate studies (Kari et al., 2008, 
2009; the information in Fig. 2 A is reprinted with permission from the Journal of Immunology and the Journal of Infectious Diseases). (B) Six monkeys 
were infected with A2497P (individual data points are plotted). RML 145 received 2 × 104 IFU/eye, RML 641 received 2 × 105 IFU/eye, and RML 642, 643, 
647, and 147 received 2 × 106 IFU/eye. Day 0 indicates the time of infection of each animal. Chlamydial burden is the geometric mean of recoverable IFU 
for both eyes of individual monkeys monitored by culture from conjunctival swabs. Clinical disease score is the aggregate clinical score (hyperemia and 
follicle formation) for both eyes of individual monkeys. The experiment was done once.JEM Vol. 208, No. 11  2219
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(RML 643, 647, and 147) all received the highest dose, 2 × 106 
IFU/eye (Fig. 2). Infection was assessed by culturing chlamydiae 
from conjunctival swabs, and ocular clinical disease was moni-
tored by scoring the upper conjunctival lids for subepithelial folli-
cles and hyperemia (Taylor et al., 1981; Kari et al., 2008). Despite 
no observable differences in the A2497 and A2497P strains’   
in vitro infection characteristics (Fig. 1), the strains exhibited 
a marked difference in pathogenicity for the monkey eye. The 
A2497P ocular infections were highly attenuated compared 
with infections produced by the plasmid-bearing A2497 pa-
rental strain (Fig. 2). A2497-infected monkeys were culture 
positive for an 8–13-wk period after infection before clear-
ance and ocular disease was moderate to severe throughout 
the culture positive period. In contrast, all monkeys chal-
lenged with the A2497P strain became infected, but the in-
fections were rapidly cleared and spontaneously resolved by 
day 14 after infection. Most notably, A2497P infections did not 
produce measurable ocular clinical pathology. A minimal ocular 
disease score was observed in several animals but was limited 
to a mild transient conjunctival hyperemia without follicle 
formation. The A2497P monkeys were infected two additional 
times using the highest dose. Group 1 animals were reinfected at 
8–10-wk intervals and group 2 animals at 3–4-wk intervals 
(Fig. 3). Remarkably, repeated A2497P infections also failed 
to evoke ocular pathology (Fig. 3). These findings were unex-
pected and in complete contrast to previous results showing 
that repeated infections with virulent plasmid-bearing trachoma 
RESULTS AND DISCUSSION
The plasmid-deficient trachoma strain is attenuated  
in nonhuman primates
A plasmid-deficient strain was made from a virulent C. trachoma-
tis serovar, a Tanzanian trachoma clinical isolate (A2497; Kari   
et al., 2008), by novobiocin treatment (O’Connell and Nicks, 
2006). This plasmid-deficient strain was designated A2497P. 
The absence of the plasmid in A2497P was verified by PCR 
analysis of all eight plasmid open reading frames (Fig. 1 A).   
De novo genomic sequencing of A2497 and A2497P revealed 
no mutations between the two chromosomes and confirmed the 
absence of the plasmid in A2497P; thus, the two trachoma 
strains were isogenic with the exception of the 7.5-kb plasmid. 
The strains did not differ in their in vitro growth characteristics 
as shown by plaque size, plaque forming kinetics, and one-step 
growth curves in cultured eukaryotic cells (Fig. 1, B and C).
We  next  investigated  the  infection  characteristics  of  the 
A2497P strain in a cynomolgus macaque (Macaca fascicularis)   
trachoma model (Taylor et al., 1981; Kari et al., 2008). The con-
junctivae of six macaques were inoculated with the A2497P 
strain, and after infection chlamydial shedding and ocular pathol-
ogy they were compared with six historic controls similarly 
infected with the virulent A2497 strain (Kari et al., 2008, 2009). 
Animals were infected in two groups. Group 1 (RML 145, 641, 
and 642) was given primary infections using three different doses 
of A2497P: 2 × 104 inclusion forming units (IFUs)/eye, 2 × 105 
IFU/eye, and 2 × 106 IFU/eye, respectively. Animals in group 2 
Figure 3.  Repeated infections of nonhuman primates with the plasmid-deficient A2497P strain do not cause ocular pathology. RML 145, 
641, and 642 were reinfected at weeks 10 and 18. RML 643, 647, and 147 were reinfected at weeks 5 and 8 (individual data points are plotted). Day 0 
indicates the time of the first infection of each animal. Arrows indicate the time of the reinfections. Chlamydial burden is the geometric mean of recover-
able IFU for both eyes of individual monkeys monitored by culture from conjunctival swabs. Clinical disease score is the aggregate clinical score (hyper-
emia and follicle formation) for both eyes of individual monkeys. The experiment was done once.2220 A trachoma vaccine in primates | Kari et al.
In contrast, three of the A2497P vaccinated monkeys (RML 
641, 647, and 642) exhibited complete protection against the 
virulent challenge. These animals did not become infected and 
exhibited no ocular pathology after challenge. The other three 
vaccinated monkeys (RML 643, 145, and 147) were infected 
after challenge but the infectious burdens were markedly less 
than unvaccinated controls. Differences in infectious burden 
were most pronounced during the first 2 wk after challenge, 
and with the exception of a single animal (RML 147), infec-
tions were cleared more rapidly than in control monkeys.   
Interestingly, despite these lower burdens, we observed no to 
marginal differences in ocular pathology between partially pro-
tected and unvaccinated controls. In no case was a vaccinated 
animal that shed chlamydiae protected against disease. Thus, 
even low levels of bacterial replication appear to be associated 
with  pathology,  suggesting  that  preventing  disease  requires 
complete  or  near  complete  inhibition  of  bacterial  growth. 
These findings are consistent with earlier observations on   
human vaccine trials using trachoma organisms (Collier, 1966), 
where vaccinated humans exhibited a reduction in chlamydial 
shedding without an associated decrease in ocular pathology. 
Table I shows a comparison of the aggregate infectious load for 
protected, partially protected, and unvaccinated controls over 
the entire culture positive period. Partially protected monkeys 
shed 95% fewer infectious organisms than unvaccinated con-
trols (partially protected monkeys: IFU range = 1,207–1,890 and   
organisms significantly augmented ocular inflammation and 
disease in macaques (Taylor et al., 1982). Interestingly, plasmid 
deficiency did not appear to alter the ability of the organism 
to infect and replicate within conjunctival epithelial cells, but 
clearly the presence of the plasmid strongly influenced the 
organism’s ability to persist in ocular tissues once infection 
had been established. These findings argue that a pathogenic 
function of the plasmid is to sustain persistent in vivo infec-
tion in its natural host. The molecular bases underlying this 
pathogenic strategy are unclear but indicate that the plasmid 
has coevolved with the organism to promote persistence, per-
haps by avoiding immune mediated effectors that are critical 
to eradication of infection. The infectious yet highly weak-
ened pathogenic phenotype of the A2497P strain suggested 
its potential utility as a live-attenuated trachoma vaccine.
Protection against virulent challenge in monkeys immunized 
with the plasmid-deficient trachoma strain
We  challenged  the  six  monkeys  that  were  given  multiple 
A2497P ocular infections with virulent A2497 trachoma 
organisms (Fig. 4). Six naive monkeys were similarly chal-
lenged  and  served  as  unvaccinated  controls.  Unvaccinated 
monkeys were uniformly infected and shed chlamydial organ-
isms over a 6–14-wk period after challenge. Infections of naive 
monkeys resulted in moderate to maximum ocular pathology 
scores at 3–4 wk after challenge that persisted for 2–4 mo. 
Figure 4.  Monkeys vaccinated with the attenuated A2497P strain are protected against a challenge infection with virulent A2497 organ-
isms. Vaccinated animals and naive unvaccinated controls were challenged 4 wk after the last vaccination. (A) Six unvaccinated control monkeys (indi-
vidual data points are plotted). (B) Six A2497P vaccinated monkeys (individual data points are plotted). Solidly protected monkeys were (RML 641, 642, 
and 647) culture negative and developed no ocular pathology after challenge. The three partially protected monkeys (RML 145, 147, and 643) had reduced 
chlamydial infection burdens; however, this reduction did not significantly alter the intensity of ocular inflammation. Chlamydial burden is the geometric 
mean of recoverable IFU for both eyes of individual monkeys monitored by culture from conjunctival swabs. Clinical disease score is the aggregate clinical 
score (hyperemia and follicle formation) for both eyes of individual monkeys. The experiment was done once.JEM Vol. 208, No. 11  2221
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Collectively, these findings support a non–antibody-mediated 
protection and suggest that either a difference in CD4 T cell 
antigen recognition or T cell effector function might be the 
explanation of enhanced vaccine-mediated immunity.
Our findings are consistent with, yet distinct from, those 
recently reported by O’Connell et al. (2007) using a plas-
mid-cured C. muridarum mouse pathogen in a mouse female 
mean = 1,549; unvaccinated monkeys: IFU range = 4,723–87, 
685 and mean = 29,577). The different immunization re-
gimes had no discernible effect on protection.
MHC class II alleles differentiate between solidly  
and partially protected macaques
Immune correlates of solidly protected versus partially pro-
tected macaques were analyzed by testing sera and tears for 
anti-chlamydial  antibodies  and  PBMC  for T  cell–specific 
anti-chlamydial cytokine production. We were not successful 
in detecting the production of chlamydial specific cytokines 
by PBMC, possibly because of the low numbers of circulating 
chlamydial-specific T cells generated after mucosal infection. 
There was no correlation between anti-chlamydial antibodies 
measured by ELISA, or serum-neutralizing antibodies and 
protective immunity (Fig. 5, A–C). However, both ELISA anti-
body and in vitro neutralization assays use intact elementary 
bodies (EBs) as antigen and are therefore restricted by their 
ability to detect a very limited number of surface antigens. We 
therefore performed a more comprehensive antigen screen 
using a C. trachomatis whole genome proteome array analysis 
(Wang et al., 2010). We observed no differences in antigen 
recognition patterns against any of the 908 C. trachomatis pro-
teins by proteome array analysis with the sera of solidly and 
partially  protected  macaques  (Table  S1).  However,  MHC   
genotyping of monkeys showed that all three solidly protected 
animals shared the same M1 haplotype in one of their MHC 
class II alleles. In contrast, none of the partially protected 
monkeys had the M1 haplotype (Fig. 5 D and Table S2). The 
small number of animals, and the fact that the experiment 
was not designed to answer this question, precluded us from 
determining if this association was statistically significant.   
Table I.  Weekly and total infectious burdens in A2497P vaccinated and unvaccinated nonhuman primates
Group/monkey 
number
Weeks of infectious burden Total infectious 
burden
1 2 3 4 5 6 7 8 9 10 11 12 13 14
IFU IFU IFU IFU IFU IFU IFU IFU IFU IFU IFU IFU IFU IFU IFU
Vaccinated
145 222 554 1,082 13 20 0 0 0 0 0 0 0 0 0 1,891
147 324 376 128 7 7 20 12 3 17 67 19 150 252 166 1,548
641 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
642 7 0 0 0 0 0 0 0 0 0 0 0 0 0 7
643 23 1,153 29 0 2 0 0 0 0 0 0 0 0 0 1,207
647 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Unvaccinated
148 86,244 582 318 125 280 31 5 0 0 0 0 97 3 0 87,685
149 37,186 2,062 226 100 426 117 69 43 61 145 321 290 113 97 41,256
150 2,911 538 352 209 596 53 15 7 7 0 0 22 0 13 4,723
644 7,874 24 18 0 3 0 0 13 0 0 0 0 0 0 7,932
648 23,367 401 25 0 0 0 0 0 0 0 0 0 0 0 23,793
649 10,885 582 466 26 7 0 10 6 2 23 0 28 37 0 12,072
The IFU was recovered from conjunctival swabs at weekly intervals after challenge. The total IFU was recovered for all culture time points. The difference between vaccinated 
and unvaccinated groups in total infectious burden is highly significant (P = 0.0026; Wilcoxon rank-sum test).
Figure 5.  Immune and genetic correlates of vaccine-mediated 
protective immunity. (A and B) Sera (A) and tear (B) IgG and IgA anti-
body titer–specific A2497 organisms were measured by ELISA (n = 2). 
Error bars show the standard deviation of the tear antibody titers mea-
sured in the left and the right eyes. (C) Serum-neutralizing antibody titers 
against A2497 organisms. Percentage of specific neutralization for each 
dilution was calculated as [(preimmune IFUs  immune IFUs)/preimmune 
IFUs] × 100. (D) MHC class I and II alleles of immunized monkeys.  
In A–C, results are shown for one of two independent experiments.2222 A trachoma vaccine in primates | Kari et al.
MATERIALS AND METHODS
Isolation  of  the  plasmid-deficient A2497P  strain. A2497-infected 
McCoy cells (MOI 1) were treated with 7 µg/ml novobiocin 4 h after infec-
tion and harvested 42 h after infection with surviving organism plaque cloned 
(Matsumoto et al., 1998). 200 individual plaques were picked and screened 
by PCR for plasmid. Plasmid negative clones were expanded and rescreened. 
A plasmid-negative clone, termed A2497P, was selected for experimentation. 
A2497P was propagated in McCoy cells, and EBs were purified by density 
gradient centrifugation (Caldwell et al., 1981). Genomic DNA was isolated 
from purified EBs of A2497P and the parent A2497 strain (Carlson et al., 
2005), and genomes were sequenced by 454 technology as previously de-
scribed (Sturdevant et al., 2010). Assembled contigs of A2497, A2497P, and the 
C. trachomatis serovar A reference strain A/HAR-13 were analyzed and com-
pared (Carlson et al., 2005). Gap closing and confirmation were done by PCR 
and capillary sequencing as previously described (Sturdevant et al., 2010). The 
annotated A2497 genome was deposited into GenBank, National Center for 
Biotechnology Information, under accession nos. CP002401 and CP002402.
In vitro characterization of A2497P. One-step growth curves and plaqu-
ing were performed in McCoy cells as previously described (Kari et al., 2008).
Nonhuman primates. Healthy adult cynomolgus macaques (M. fascicularis) 
maintained at the Rocky Mountain Laboratories were cared for under stan-
dard practices implemented by the Rocky Mountain Veterinary Branch. 
Monkeys were housed separately when being used for experimental studies. 
All handling procedures were reviewed and affirmed by the Animal Care 
and Use Committee at Rocky Mountain Laboratories and work was con-
ducted in full compliance with the Guide for Care and Use of Laboratory 
Animals. The facilities are fully accredited by the American Association for 
Accreditation of Laboratory Animal Care.
Infection of macaques. Infections were done by direct instillation of chla-
mydiae onto the upper and lower conjunctival surfaces (20 µl per eye) of both 
eyes (Kari et al., 2008). Infections with A2497P for the evaluation of attenua-
tion were done as follows: one monkey received 2 × 104 IFU/eye (RML 145), 
one animal 2 × 105 IFU/eye (RML 641), and four animals 2 × 106 IFU/eye 
(RML 642, 643, 647, and 147). After the primary infection, all six monkeys re-
ceived two additional infections of 2 × 106 IFU/eye at 4- or 8-wk intervals. For 
comparison of virulence, A2497P infected monkeys were compared with six 
historic control animals similarly infected with the A2497 plasmid-positive 
parent strain at 2 × 104 IFU/eye in two recent nonhuman primate studies (Kari   
et al., 2008, 2009). 30 d after the last infection, the six A2497P immunized 
monkeys and six unimmunized naive control monkeys were simultaneously 
challenged conjunctivally with the virulent A2497 parental strain at 2 × 104 
IFU/eye.
Evaluation of infection and disease. Clinical evaluation of infected mon-
keys was performed weekly. Evaluations were done in a blinded manner by a 
veterinarian primatologist. Monkeys were scored for hyperemia and follicle 
formation on the upper conjunctival surfaces in both eyes, as described by 
Taylor et al. (1981). Hyperemia was scored as follows: 0, no hyperemia; 1, mild 
hyperemia; and 2, severe hyperemia. Subepithelial conjunctival follicles were 
scored as follows: 0, no follicles; 1, 1–3 follicles; 2, 4–10 follicles; 3, >10 folli-
cles; and 4, follicles too numerous to count. The scores recorded for the upper 
conjunctival surfaces of both eyes were added for each animal and termed the 
clinical response score. The highest possible score was 12 (Kari et al., 2009). 
Chlamydial shedding was monitored by culturing organisms in monolayers of 
cycloheximide-treated McCoy cells from swabs taken from the upper and 
lower conjunctival surfaces (Kari et al., 2009). Day 0 samples were taken before 
infection. Tears and blood were collected weekly for serological analysis.
ELISA of serum and tear antibody responses. Serum and tear chlamydial-
specific IgA and IgG antibody titers were assayed by ELISA using forma-
lin fixed serovar A EBs as previously described (Kari et al., 2009). Antibody 
titers were expressed as the highest dilution giving an absorbance (OD) value 
of at least three times above the background.
genital tract infection model. These investigators described no 
difference in infection characteristics between the plasmid-
bearing and -deficient mouse strain in the lower and upper 
(oviduct) genital tract of mice but, curiously, found that infec-
tion of oviduct tissue with the plasmid-negative strain failed 
to induce inflammatory pathology. The molecular basis for 
this  difference  in  infection-independent  pathological  out-
come in mouse genital tissues was associated with the failure 
of the plasmid negative strain to stimulate TLR2 dependent 
cytokine production, a finding implicating differential TLR 
pattern recognition expression between cervico-vaginal and 
oviduct  tissues.  Lastly,  the  C.  muridarum  plasmid-deficient 
strain did not afford protection against infection after chal-
lenge with virulent plasmid-bearing organisms but did pro-
tect against upper genital tract pathology. In our study, we 
similarly show that the human C. trachomatis serovar A plasmid- 
deficient and plasmid-bearing strains have similar infection 
potency for conjunctival epithelial cells of nonhuman pri-
mates and that infection with plasmid-deficient organisms 
fails to produce measurable ocular inflammatory pathology 
(Fig. 2). Of note, however, as it is important to vaccine devel-
opment, we show that infection with the plasmid-deficient 
human strain provides significant protection against ocular 
infection (Fig. 4). We also describe an additional hereto un-
recognized pathogenic property of the chlamydial plasmid: 
the propensity of plasmid-bearing organisms to cause persis-
tent infection that results in a sustained ocular inflammatory 
response (Fig. 2), a property which might be unique to human 
strains and infection. Nevertheless, the studies conducted in both 
mice and nonhuman primate models support an important 
role of the plasmid in chlamydial pathogenesis and the use of 
plasmid-deficient strains as live-attenuated vaccines.
Concluding remarks
We have shown the plasmid-deficient trachoma strain is highly 
attenuated for the monkey eye, demonstrating that the plasmid is 
a key virulence factor important to the pathogenesis of infection. 
As the nonhuman primate model has an excellent predictive 
value for human infection and disease, these findings strongly 
support a similar pathogenic role for the plasmid in human infec-
tions. We have also shown that vaccination with the attenuated 
strain generated an immune response that protected macaques 
against challenge with virulent trachoma organisms. Extrapola-
tion of these findings to endemic trachoma regions suggests that 
a live-attenuated vaccine with this degree of efficacy would sig-
nificantly reduce trachoma infection rates and transmission fre-
quency, which would interrupt the cycles of reinfection, the 
primary epidemiological risk factor which drives scarring inflam-
matory disease and blindness. As the protective effect of vaccina-
tion would be sustainable in the population, the live-attenuated 
trachoma vaccine described herein could ultimately help control 
this ancient and scourging blinding disease. Our findings may also 
be beneficial in the design and development of a live-attenuated 
vaccine for the prevention of chlamydial sexually transmitted   
infections,  which  are  a  leading  cause  of  bacterial  sexually 
transmitted diseases and a risk factor for HIV transmission.JEM Vol. 208, No. 11  2223
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In  vitro  serum  neutralization  assays. In vitro infection neutralization   
activities of serum antibodies against serovar A EBs were measured as previ-
ously described (Su et al., 1990), except that antibody dilutions were incubated 
with 105 IFU and during the infection plates were centrifuged for 1 h and 
rocked for 30 min at 37 C. Percent specific neutralization for each dilution was 
calculated as [(preimmune IFUs  immune IFUs)/preimmune IFUs] × 100.
MHC class I and II haplotype determination. MHC class I and class II 
haplotypes were determined from whole blood by the Wisconsin National 
Primate Research Center University of Wisconsin-Madison.
Proteome  array. A C. trachomatis whole genome scale proteome array 
ELISA was used to profile serum antibody responses in monkeys as described 
previously (Wang et al., 2010). Primate antisera were preabsorbed with bac-
terial lysates containing glutathione S-transferase (GST) alone before react-
ing with the microplate-immobilized C. trachomatis GST fusion proteins. 
The reactivity was detected using a secondary antibody conjugate and mea-
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Statistical analyses. Statistical analyses were done using the nonparametric 
Wilcoxon rank-sum test. Differences were considered significant at a value 
of P < 0.05.
Online supplemental material. Table S1 shows the result of the C. tracho-
matis whole genome proteome array analysis. Table S2 shows the MHC   
alleles of the vaccinated monkeys. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20111266/DC1.
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